BR0014408A - Antìgenos do vìrus do herpes simples imunologicamente significativos; e métodos para identificação e utilização dos mesmos - Google Patents

Antìgenos do vìrus do herpes simples imunologicamente significativos; e métodos para identificação e utilização dos mesmos

Info

Publication number
BR0014408A
BR0014408A BR0014408-8A BR0014408A BR0014408A BR 0014408 A BR0014408 A BR 0014408A BR 0014408 A BR0014408 A BR 0014408A BR 0014408 A BR0014408 A BR 0014408A
Authority
BR
Brazil
Prior art keywords
antigens
cells
hsv
methods
identifying
Prior art date
Application number
BR0014408-8A
Other languages
English (en)
Inventor
David M Koelle
Hongbo Chen
Lawrence Corey
Nancy Ann Hosken
Patrick Mcgowan
Steven P Fling
Christine M Posavad
Original Assignee
Univ Washington
Corixa Corp
Hutchinson Fred Cancer Res
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Washington, Corixa Corp, Hutchinson Fred Cancer Res filed Critical Univ Washington
Publication of BR0014408A publication Critical patent/BR0014408A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16622—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

"ANTìGENOS DO VìRUS DO HERPES SIMPLES IMUNOLOGICAMENTE SIGNIFICATIVOS; E MéTODOS PARA IDENTIFICAçãO E UTILIZAçãO DOS MESMOS". A invenção fornece antígenos de HSV que são úteis para a prevenção e tratamento de infecção por HSV. Descreve-se epítopos confirmados como sendo reconhecidos por células T derivadas de lesões herpéticas. As células T que têm especificidade para os antígenos da invenção demonstraram atividade citóxica contra células carregadas com epítopos de peptídeos codificados de modo viral, e em muitos casos, contra células infectadas com HSV. A identificação de antígenos imunogênicos responsáveis pela especificidade de células T fornece estratégias antivirais, terapêuticas e profiláticas, aperfeiçoadas. As composições que contêm os antígenos ou polinucleotídeos que codificam os antígenos da invenção fornecem vacinas eficazmente direcionadas para prevenção e tratamento de infecção por HSV.
BR0014408-8A 1999-09-30 2000-09-28 Antìgenos do vìrus do herpes simples imunologicamente significativos; e métodos para identificação e utilização dos mesmos BR0014408A (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US15718199P 1999-09-30 1999-09-30
US20366000P 2000-05-12 2000-05-12
US21810400P 2000-07-13 2000-07-13
PCT/US2000/026663 WO2001023414A2 (en) 1999-09-30 2000-09-28 Immunologically significant herpes simplex virus antigens

Publications (1)

Publication Number Publication Date
BR0014408A true BR0014408A (pt) 2002-07-02

Family

ID=27387973

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0014408-8A BR0014408A (pt) 1999-09-30 2000-09-28 Antìgenos do vìrus do herpes simples imunologicamente significativos; e métodos para identificação e utilização dos mesmos

Country Status (16)

Country Link
US (2) US6413518B1 (pt)
EP (1) EP1222281B1 (pt)
JP (2) JP2003512305A (pt)
KR (1) KR20020048944A (pt)
CN (1) CN1376201A (pt)
AT (1) ATE345389T1 (pt)
AU (2) AU782676B2 (pt)
BR (1) BR0014408A (pt)
CA (1) CA2379623C (pt)
DE (1) DE60031874D1 (pt)
HK (1) HK1044799A1 (pt)
NO (1) NO20021479L (pt)
NZ (2) NZ531980A (pt)
PL (1) PL355265A1 (pt)
TR (1) TR200200838T2 (pt)
WO (1) WO2001023414A2 (pt)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL141044A0 (en) * 1998-08-07 2002-02-10 Univ Washington Innunological herpes simplex virus antigens and methods for use thereof
US6821519B2 (en) * 2000-06-29 2004-11-23 Corixa Corporation Compositions and methods for the diagnosis and treatment of herpes simplex virus infection
WO2003011893A2 (en) * 2001-07-31 2003-02-13 University Of Washington Immunologically significant herpes simplex virus antigens and methods for using same
AU2003252052A1 (en) * 2002-07-18 2004-02-09 University Of Washington Rapid, efficient purification of hsv-specific t-lymphocytes and hsv antigens identified via same
CA2503693A1 (en) 2002-10-29 2004-05-13 Coley Pharmaceutical Group, Ltd. Use of cpg oligonucleotides in the treatment of hepatitis c virus infection
EP2289547B1 (en) * 2003-09-12 2015-12-16 Agenus Inc. Vaccine for treatment and prevention of herpes simplex virus infection
EP1774332B1 (en) * 2004-05-24 2010-01-20 Baylor Research Institute Immune response assessment method
US9012184B2 (en) * 2006-02-08 2015-04-21 Illumina Cambridge Limited End modification to prevent over-representation of fragments
CA2658484A1 (en) * 2006-07-20 2008-01-24 Vical Incorporated Compositions and methods for vaccinating against hsv-2
US20100166808A1 (en) * 2008-11-17 2010-07-01 Giovanni Marco Pauletti Method of Facilitating Intracellular Uptake or Transcellular Transport of Cargo Using Nanocarriers Containing Optimal Surface Densities of Integrin-Specific Ligands
US8460674B2 (en) * 2009-02-07 2013-06-11 University Of Washington HSV-1 epitopes and methods for using same
EP2408812B1 (en) 2009-03-17 2015-12-16 CardioVax, LLC Immunomodulatory methods and systems for treatment and/or prevention of atherosclerosis and related proteins, peptides and compositions
WO2010115172A2 (en) 2009-04-03 2010-10-07 University Of Washington Antigenic peptide of hsv-2 and methods for using same
CN102458463B (zh) 2009-05-22 2017-01-18 健诺西生物科学公司 针对ⅱ型单纯疱疹病毒的疫苗：诱发免疫应答的组合物和方法
EP2305277A1 (en) * 2009-09-18 2011-04-06 Forskarpatent I Syd AB Use of tolerogenic dendritic cells in treatment and prevention of atherosclerosis
WO2011060329A1 (en) 2009-11-14 2011-05-19 Kuang-Yuh Chyu Immunomodulatory methods and systems for treatment and/or prevention of atherosclerosis
CA2817543A1 (en) 2010-11-12 2012-06-07 Cedars-Sinai Medical Center Immunomodulatory methods and systems for treatment and/or prevention of hypertension
RU2013126628A (ru) 2010-11-12 2014-12-20 Седарс-Синаи Медикал Сентер Иммуномодулирующие способы и системы для лечения и/или предотвращения аневризм
CA2856697A1 (en) 2010-11-24 2012-06-07 Genocea Biosciences, Inc. Vaccines against herpes simplex virus type 2: compositions and methods for eliciting an immune response
EA033467B1 (ru) * 2011-01-31 2019-10-31 Univ Pennsylvania Молекула нуклеиновой кислоты для индукции иммунного ответа против герпесвируса и ее применение
CN107875382B (zh) * 2011-11-11 2024-03-08 变异生物技术公司 用于治疗巨细胞病毒的组合物和方法
JP6199878B2 (ja) 2011-11-23 2017-09-20 ジェノセア バイオサイエンシーズ， インコーポレイテッド 単純ヘルペスウイルス２型に対する核酸ワクチン：免疫応答を誘発する組成物及び方法
PT2850431T (pt) 2012-05-16 2018-07-23 Immune Design Corp Vacinas para hsv-2
ES2843277T3 (es) * 2014-06-26 2021-07-16 Heidelberg Immunotherapeutics Gmbh Aplicación tópica para un anticuerpo anti-VHS
EP3365009A4 (en) * 2015-10-22 2019-07-03 ModernaTX, Inc. VACCINES AGAINST HERPES SIMPLEX VIRUS
US10350288B2 (en) 2016-09-28 2019-07-16 Genocea Biosciences, Inc. Methods and compositions for treating herpes
US20190350981A1 (en) * 2017-01-20 2019-11-21 Atara Biotherapeutics, Inc. Methods of treating multiple sclerosis using autologous t cells
WO2020190750A1 (en) 2019-03-15 2020-09-24 Modernatx, Inc. Hiv rna vaccines
US20230272340A1 (en) * 2020-08-13 2023-08-31 Rootpath Genomics, Inc. Compositions and methods for antigen identification
WO2022212289A1 (en) * 2021-03-29 2022-10-06 Rational Vaccines, Inc. Mutant herpesvirus and vaccine compositions

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4859587A (en) 1984-06-04 1989-08-22 Institut Merieux Recombinant herpes simplex viruses, vaccines and methods
CA2088600C (en) 1990-08-02 1999-11-16 Rae L. Burke Herpes simplex virus vp16 vaccines
CA2090295A1 (en) 1992-02-03 1993-08-04 Anthony B. Nesburn Process for the expression of herpes simplex virus type 1 glycoprotein e and methods of use
GB9325496D0 (en) 1993-12-14 1994-02-16 Smithkline Beecham Biolog Vaccines
DE69637147T2 (de) 1995-07-28 2008-03-06 Marie Curie Cancer Care Transportproteine und deren verwendungen
EP0948508A4 (en) * 1996-11-04 2001-11-07 Smithkline Beecham Corp NEW CODING SEQUENCES FOR HERPES SIMPLEX TYPE 2 VIRUS
EP0984790A1 (en) * 1997-06-02 2000-03-15 Chiron Corporation Herpes simplex virus vp22 vaccines and methods of use
US6169175B1 (en) * 1997-08-06 2001-01-02 Centers For Disease Control And Prevention Preparation and use of recombinant influenza A virus M2 construct vaccines
AU3102799A (en) * 1998-03-20 1999-10-11 Genzyme Corporation Enhanced anti-tumor immunity

Also Published As

Publication number Publication date
EP1222281A2 (en) 2002-07-17
US20020155122A1 (en) 2002-10-24
JP2012214478A (ja) 2012-11-08
CA2379623A1 (en) 2001-04-05
AU7836400A (en) 2001-04-30
AU2005234654A1 (en) 2005-12-15
NZ517959A (en) 2004-05-28
JP5602188B2 (ja) 2014-10-08
WO2001023414B1 (en) 2002-02-28
DE60031874D1 (de) 2006-12-28
JP2003512305A (ja) 2003-04-02
CA2379623C (en) 2014-09-09
HK1044799A1 (zh) 2002-11-01
ATE345389T1 (de) 2006-12-15
NO20021479D0 (no) 2002-03-25
NZ531980A (en) 2005-04-29
US6413518B1 (en) 2002-07-02
EP1222281B1 (en) 2006-11-15
WO2001023414A2 (en) 2001-04-05
WO2001023414A3 (en) 2001-11-08
NO20021479L (no) 2002-05-03
US6962709B2 (en) 2005-11-08
AU782676B2 (en) 2005-08-18
PL355265A1 (en) 2004-04-05
KR20020048944A (ko) 2002-06-24
AU2005234654B2 (en) 2008-04-24
CN1376201A (zh) 2002-10-23
TR200200838T2 (tr) 2002-06-21

Similar Documents

Publication Publication Date Title
BR9912671A (pt) Antìgenos imunológicos para o vìrus de herpes simples e métodos para sua utilização
NO20021479D0 (no) Immunologiske signifikante herpes simplex virus antigener og metoder for å identifisere og å bruke dem
LU93101I2 (fr) Imlygic-talimogene laherparepvec
BR9712366A (pt) Gene de gd2 do vírus do herpes simples hsv2 isolado, plasmídeo compreendendo o mesmo, e, processos de induzir, em indivíduo, uma resposta imune contra hsv2 gd2, de tratar um indíviduo que está infectado com hsv, e, de prevenir que um indivíduo fique infectado com hsv
BR9912653A (pt) Vìrus de herpes atenuado, cepa de vìrus, célula dendrìtica, processo para produzir um célula, composição farmacêutica, uso de um vìrus, e, processo para executar a terapia de gene em um paciente humano ou animal ou para tratar ou prevenir uma infecção patogênica ou câncer para tratar paciente animal
EP2316479B8 (en) Pharmaceutical compositions comprising immunologically active herpes simplex virus (HSV) protein fragments
MX2023012368A (es) Vacuna de virus.
BR0109928A (pt) Uso de um herpes vìrus atenuado, e, método para estimular uma resposta imune em um indivìduo humano ou animal, ou para tratar ou prevenir uma infecção patogênica ou câncer em um indivìduo humano ou animal
AR005750A1 (es) Composicion farmaceutica para tratar o prevenir infecciones con zoster en personas infectadas con el virus de varicela zoster y procedimiento para preparar dicha composicion
BR0012985A (pt) Vacina, bactéria, uso da mesma, e composição farmacêutica e métodos de tratamento ou prevenção de doença mediada por hsv em um hospedeiro humano ou animal e de uma infecção viral da mucosa de um hospedeiro humano ou animal

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]